Sapience Therapeutics Provides Positive Data Update from Phase 2 Trial of Lucicebtide Plus SOC in Patients with Glioblastoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
PRNewsWire
·
2026-05-22
·
via The Tech Buzz - Press Releases
Long-term follow-up reinforces PFS and OS benefit of lucicebtide plus standard of care in ndGBM: mPFS project…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。